CELLULAR-RESPONSES AND ANTIBODY-RESPONSES TO EQUINE HERPESVIRUS-1 ANDHERPESVIRUS-4 FOLLOWING VACCINATION OF HORSES WITH MODIFIED-LIVE AND INACTIVATED VIRUSES
Ja. Ellis et al., CELLULAR-RESPONSES AND ANTIBODY-RESPONSES TO EQUINE HERPESVIRUS-1 ANDHERPESVIRUS-4 FOLLOWING VACCINATION OF HORSES WITH MODIFIED-LIVE AND INACTIVATED VIRUSES, Journal of the American Veterinary Medical Association, 206(6), 1995, pp. 823-832
The ability of monovalent and bivalent equine herpesvirus (EHV) vaccin
es to stimulate cellular and antibody responses to EHV-1 and EHV-4 was
compared in healthy horses. Comparison of data from lymphocyte blasto
genesis tests in which live viruses were used as antigens and that wer
e conducted prior to vaccination and after 2 vaccinations revealed tha
t houses given modified-live EHV-1 had significant increases in prolif
erative responses to EHV-1 (P = 0.03) and EHV-4 (P = 0.04). Responses
to EHV-1 and EHV-4 in horses given the inactivated-virus bivalent vacc
ine were less; however, significant differences were not noticed when
postvaccinal lymphocyte blastogenesis tests were compared between the
groups of vaccinees. Interleukin-2 activity was not detected in leukoc
yte cultures from either group of vaccinees following stimulation with
live EHV-1 or EHV-4; however, interferon activity was found in simila
r cultures from both groups of vaccinees. For EHV-4, interferon activi
ty in cultures from both groups of vaccinees was significantly (P < 0.
05) greater than that in leukocyte cultures from unvaccinated controls
. Both vaccines induced significant (P < 0.05) increases in serum anti
bodies that neutralized EHV-1 infectivity. The ELISA for EHV-1 and EHV
-4 antibodies revealed that both vaccines induced significant (P < 0.0
5) increases (compared with preinoculation values) in antibodies react
ive with these 2 types of EHV. Total serum antibody responses, as meas
ured by ELISA, to EHV-1 and EHV-4 were significantly (P < 0.05) higher
in horses that received the bivalent inactivated-virus vaccine, compa
red with that in horses that received monovalent vaccine. Evaluation o
f these data revealed that vaccination with modified-live EHV-1 can st
imulate cellular and antibody responses that cross-react with EHV-4.